NCT04239989 is a Phase 1 clinical trial of Itacitinib in Bronchiolitis Obliterans, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT04239989?

NCT04239989 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT04239989?

Interventions in NCT04239989: Itacitinib, Itacitinib Adipate.

What condition does NCT04239989 study?

NCT04239989 studies Bronchiolitis Obliterans.

Is NCT04239989 still recruiting?

NCT04239989 is currently terminated. Last updated 10 November 2025.

Last reviewed 2025-11-10 · How we verify

NCT04239989

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

Terminated Phase 1 Last updated 10 November 2025

What this trial tests

Phase 1 trial testing Itacitinib in Bronchiolitis Obliterans in 8 participants. Terminated before completion.

Timeline

8 October 2021

Primary endpoint
31 October 2025

31 October 2025

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	8 October 2021
Primary completion	31 October 2025
Estimated completion	31 October 2025
Sites	1 location across United States

Drugs / interventions tested

Itacitinib — full drug profile →
Itacitinib Adipate — full drug profile →

Conditions studied

Bronchiolitis Obliterans — all drugs for Bronchiolitis Obliterans →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 75, any sex, with Bronchiolitis Obliterans. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction.
Bos S, Pradère P, Beeckmans H, Zajacova A, et al · · 2023 · cited 5× · PMID 37295951 · DOI 10.1124/pharmrev.123.000834

Verify or expand the search:

Other trials of Itacitinib

Trials testing the same drug.

NCT05660421 — Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors · Phase 2 · withdrawn
NCT05364762 — Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergo · Phase 2 · active not recruiting
NCT05063110 — Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB · Phase 2 · completed
NCT04859946 — Itacitinib for the Prevention of Graft Versus Host Disease · Phase 2 · active not recruiting
NCT04446182 — Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD · Phase 2 · terminated

Other recruiting trials for Bronchiolitis Obliterans

Currently open trials in the same condition.

NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
NCT05922761 — BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) · Phase 2 · recruiting
NCT04604522 — Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04239989 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04239989.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing